Scholarlink

Background <p>Metabolic dysfunction-associated steatotic liver disease (MASLD) coexists with type 2 diabetes and is rising in Japan. Liver fibrosis progression in MASLD causes adverse outcomes, highlighting the need for early risk stratification. The utility of the Metabolic Dysfunction–Associated Fibrosis 5 (MAF-5) score has not been assessed in Japanese populations, especially among individuals with type 2 diabetes. Herein, the clinical relevance of the MAF-5 score was assessed in Japanese patients with MASLD.</p> Methods <p>This prespecified secondary analysis used data from a study titled “A Study to Estimate the Severity of MAFLD Using Continuous Glucose Monitoring.” Sixty-six patients diagnosed with metabolic dysfunction–associated fatty liver disease (MAFLD) underwent vibration-controlled transient elastography. All participants were subsequently confirmed to meet the revised diagnostic criteria for MASLD. The MAF-5 score and FIB-4 index were calculated for each participant. Correlations between these scores and liver stiffness measurement (LSM) were assessed using Spearman’s rank correlation coefficient. Significant fibrosis was defined as LSM ≥ 8.0&#xa0;kPa. The predictive performance of each score was evaluated using the area under the receiver operating characteristic curve (AUROC).</p> Results <p>The final analysis included 57 participants (28 with type 2 diabetes). The MAF-5 score significantly correlated with LSM, whereas the FIB-4 index did not. These associations were consistent regardless of diabetes status. The AUROC for the MAF-5 score was higher than that for the FIB-4 index.</p> Conclusion <p>The MAF-5 score may serve as a useful noninvasive marker for predicting liver fibrosis in Japanese patients with MASLD, regardless of diabetes status.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical utility of the MAF-5 score for assessing MAFLD/MASLD in a Japanese population with obesity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月21日

查看全文
  • Hayato Fukumitsu,
  • Kazuhiko Sakaguchi,
  • Marika Nishisaka,
  • Yukari Katsura,
  • Yasuko Morita,
  • Natsu Otowa-Suematsu,
  • Tomoko Yamada,
  • Yoshihiko Yano,
  • Michiko Takahashi,
  • Shun-Ichiro Asahara,
  • Wataru Ogawa

摘要

Background

Metabolic dysfunction-associated steatotic liver disease (MASLD) coexists with type 2 diabetes and is rising in Japan. Liver fibrosis progression in MASLD causes adverse outcomes, highlighting the need for early risk stratification. The utility of the Metabolic Dysfunction–Associated Fibrosis 5 (MAF-5) score has not been assessed in Japanese populations, especially among individuals with type 2 diabetes. Herein, the clinical relevance of the MAF-5 score was assessed in Japanese patients with MASLD.

Methods

This prespecified secondary analysis used data from a study titled “A Study to Estimate the Severity of MAFLD Using Continuous Glucose Monitoring.” Sixty-six patients diagnosed with metabolic dysfunction–associated fatty liver disease (MAFLD) underwent vibration-controlled transient elastography. All participants were subsequently confirmed to meet the revised diagnostic criteria for MASLD. The MAF-5 score and FIB-4 index were calculated for each participant. Correlations between these scores and liver stiffness measurement (LSM) were assessed using Spearman’s rank correlation coefficient. Significant fibrosis was defined as LSM ≥ 8.0 kPa. The predictive performance of each score was evaluated using the area under the receiver operating characteristic curve (AUROC).

Results

The final analysis included 57 participants (28 with type 2 diabetes). The MAF-5 score significantly correlated with LSM, whereas the FIB-4 index did not. These associations were consistent regardless of diabetes status. The AUROC for the MAF-5 score was higher than that for the FIB-4 index.

Conclusion

The MAF-5 score may serve as a useful noninvasive marker for predicting liver fibrosis in Japanese patients with MASLD, regardless of diabetes status.